https://www.selleckchem.com/pr....oducts/trastuzumab-d
Infants born at extremely low gestational age are at high risk for bronchopulmonary dysplasia and continuing lung disease. There are no early clinical biomarkers for pulmonary outcome and limited therapeutic interventions. We performed global proteomics of premature infant tracheal aspirate (TA) and plasma to determine the composition and source of lung fluid proteins and to identify potential biomarkers of respiratory outcome. TA samples were collected from intubated infants in the TOLSURF cohort before and after nitric
Like
Comment
Share
